The treatment of DCs with this inhibitor increases their ability to stimulate CD8 antigen-specific T cell lines in vitro and increases tumor cell lysis using antigen-specific CD8+ T cell lines derived from cancer patients [120]. This evidence concerns the gene CD8A and neoplasm.